Kell Glycoprotein Research Articles

A new low-incidence antigen in the Kell blood group system: VLAN (KEL25).

A multilaboratory investigation has identified a new low-incidence antigen "VLAN' on the red cells of a blood donor. The VLAN antigen is destroyed by 2-aminoethylisothiouronium bromide treatment of the donor's red cells suggesting an association with the Kell system. Monoclonal antibody-specific immobilization of erythrocyte antigen analysis with anti-VLAN and with several mouse monoclonal antibodies directed at epitopes on the Kell glycoprotein gave positive results, indicating that the VLAN antigen is located on the Kell glycoprotein. The VLAN red blood cells have the common Kell phenotype: KEL:-1,2,-3,4,5,-6,7,-10,11,12,13,14,-17,18,19,-21,22,-23,-24. Additional serologic data indicate that the VLAN antigen is not part of any other ISBT blood group system, collection or series. A family study showed that the VLAN antigen is inherited since the red cells of two sisters and one niece of the propositus are also VLAN+. The ISBT Working Party on Terminology for Red Cell Surface Antigens has assigned VLAN to the Kell blood group system as KEL25 (number for computer listings 006025).

Kell typing by allele-specific PCR (ASP).

The Kell blood group system is important in transfusion medicine, and the Kell antigen (K1) is probably second in importance to Rh D as an immunogen in alloimmunized pregnancies which cause haemolytic disease of the newborn. The K/k (K1/K2) blood group polymorphism has been recently defined. A point mutation changes Thr193 (k) to Met193 (K) in the Kell glycoprotein. The mutation which creates K destroys a consensus N-glycan addition site. We describe a simple PCR test for K blood group typing. The test is based on the use of an allele-specific K-primer. We have shown the test to give results in complete concordance with serologically defined Kell blood group status using 65 genomic DNA samples derived from both amniocytes and peripheral blood lymphocytes. The test is suitable for the prenatal determination of Kell type.

A New Low-Incidence Antigen in the Kell Blood Group System: VLAN (KEL25)

A multilaboratory investigation has identified a new low-incidence antigen ‘VLAN’ on the red cells of a blood donor. The VLAN antigen is destroyed by 2-aminoethylisothiouronium bromide treatment of the donor’s red cells suggesting an association with the Kell system. Monoclonal antibody-specific immobilization of erythrocyte antigen analysis with anti-VLAN and with several mouse monoclonal antibodies directed at epitopes on the Kell glycoprotein gave positive results, indicating that the VLAN antigen is located on the Kell glycoprotein. The VLAN red blood cells have the common Kell phenotype: KEL:-1,2,—3,4,5,— 6,7,-10,11,12,13,14,-17,18,19,-21,22,-23,-24. Additional serologic data indicate that the VLAN antigen is not part of any other ISBT blood group system, collection or series. A family study showed that the VLAN antigen is inherited since the red cells of two sisters and one niece of the propositus are also VLAN+. The ISBT Working Party on Terminology for Red Cell Surface Antigens has assigned VLAN to the Kell blood group system as KEL25 (number for computer listings 006025).

A Novel Common Kell Antigen, TOU, and Its Spatial Relationship to Other Kell Antigens

A 47-year-old native American (TOU) was admitted to hospital for hip surgery. His serum agglutinated all red blood cells (RBCs) tested except Ko and DTT- treated RBCs and was weakly reactive with RBCs known to have a weak expression of Kell antigens, namely Kmod, McLeod, Kp(a+b-) (KEL:3,-4) and K:-13 (KEL:-13) phenotypes. RBCs from three siblings, a son and a daughter were incompatible with TOU’s antibody. TOU’s RBCs had the common Kell phenotype: K- k+ Kp(a-b+c-) Ku+ Js(a-b+) Ul(a-) K:ll, -17 K:14,-24 K: 12,13,18,19, 22,-23 (KEL:-1,2,-3,4,5,-6,7,-10,11,12,13,14,-17,18,19,-21,22,-23,-24). Since TOU’s RBCs were not agglutinated by an unidentified Kell-related antibody (IAN), tests were performed to show that TOU and IAN were mutually compatible. IAN is a Latino female hospitalised for a hysterectomy. The TOU antigen was shown to be located on the Kell glycoprotein by a monoclonal antibody immobilisation of erythrocyte antigen (MAIEA) assay. The unique pattem of reactivity obtained with TOU and IAN antibodies using this assay indicated the TOU epitope to be in an area remote from other Kell antigens, namely K, k, Kp^a, Kp^b, Kp^c, Ku, Js^a, Js^b Ul^a, K11, K12, K13, K14, Wk\ K18, K19, K22 and K24 (KEL1, KEL2, KEL3, KEL4, KEL5, KEL6, KEL7, KEL11, KEL12, KEL13, KEL14, KEL17, KEL18, KEL19, KEL21, KEL22 and KEL24) but close to the low-incidence antigen K23 (KEL23). Investigation of antibodies to previously identified antigens on the Kell glycoprotein by MAIEA using the mouse monoclonal antibodies BRIC18, BRIC68, BRIC107 and BRIC203 has identified six patterns of reactivity and has provided evidence for Kp^c being located in the same region as Kp^a and Kp^b.

Application of the MAIEA assay to the Kell blood group system.

The monoclonal antibody-specific immobilisation of erythrocyte antigens (MAIEA) test has been employed to investigate the Kell system using five monoclonal antibodies which recognise high frequency epitopes on the 93,000-molecular weight Kell glycoprotein: BRIC 18, BRIC 68, BRIC 107, BRIC 203 and 6-22. BRIC 107, which has anti-k-like (KEL2) specificity, identifies a distinct epitope, whilst competitive binding assays suggested that BRIC 203 (anti-Kpbc), BRIC 18, BRIC 68 and 6-22 (anti K14) comprise an overlapping set of epitopes. The MAIEA assay has been very successful in confirming the assignment of most of the Kell and para-Kell antigens to the Kell protein. Due to the competitive nature of the assay and the fact that the monoclonal antibodies bind to different regions, the results also suggest the relative positions of some of the Kell antigens on the Kell protein; these appear to be located in at least five spatially distinct regions.

Application of the MAIEA Assay to the Kell Blood Group System

The monoclonal antibody-specific immobilisation of erythrocyte antigens (MAIEA) test has been employed to investigate the Kell system using five monoclonal antibodies which recognise high frequency epitopes on the 93,000-molecular weight Kell glycoprotein: BRIC 18, BRIC 68, BRIC 107, BRIC 203 and 6-22. BRIC 107, which has anti-k-like (KEL2) specificity, identifies a distinct epitope, whilst competitive binding assays suggested that BRIC 203 (anti-Kp^bc), BRIC 18, BRIC 68 and 6-22 (anti K14) comprise an overlapping set of epitopes. The MAIEA assay has been very successful in confirming the assignment of most of the Kell and para-Kell antigens to the Kell protein. Due to the competitive nature of the assay and the fact that the monoclonal antibodies bind to different regions, the results also suggest the relative positions of some of the Kell antigens on the Kell protein; these appear to be located in at least five spatially distinct regions.

Monoclonal antibodies against Kell glycoprotein: serology, immunochemistry and quantification of antigen sites.

Monoclonal antibodies BRIC 18, BRIC 68, BRIC 107 and BRIC 203 recognize high-frequency epitopes absent from erythrocytes expressing the Ko phenotype. BRIC 107 has anti-k (K2)-like specificity. BRIC 203 has a unique specificity denoted anti-Kpbc. All four monoclonal antibodies identify an M(r) 95,600 erythrocyte membrane protein by immunoprecipitation from radio-iodinated erythrocytes. In quantitative binding studies using IgG it is estimated that there are from 2000 (BRIC 18) to 4000 (BRIC 68) copies of the Kell glycoprotein per erythrocyte. Using Fab fragments the estimates are in the range 4000 (BRIC 18) to 18,000 (BRIC 68) copies. In competitive binding assays the four epitopes defined by the BRIC monoclonal antibodies fall into two non-overlapping groups. The first group comprises BRIC 18, BRIC 68, BRIC 203 and an antibody (6-22) with anti-K14 specificity. The second group contains BRIC 107 and two further anti-k-like monoclonal antibodies (BS45 and OSK5). The results suggest that the polymorphisms encoded at the K/k and Kpa/Kpb/Kpc loci may be located in two spatially distinct regions of the Kell glycoprotein(s).

Monochonal antibody-specific immobilisation of erythrocyte antigens (MAIEA) A new technique to selectively determine antigenic sites on red cell membranes

A new assay, the monoclonal antibody-immobilization of erythrocyte antigens (MAIEA) is described for the assignment of red cell antigens recognised by human allo-antisera, to particular membrane components of the red cell membrane. This technique detects tri-molecular complexes formed by the reaction of a human antibody and a mouse antibody with a particular red cell protein. A positive reaction, in an ELISA-type detection procedure, occurs if the epitopes recognised by the human and mouse antibodies are present on the same membrane component but different regions. The MAIEA assay has been developed to investigate blood group antigens and in this report its application to the study of the Lutheran, Yt and Kell blood group systems is described. The technique has been used to show that the Lu a and Lu 3 antigens are carried on the Lutheran glycoprotein, Yt a and Yt b on the enzyme acetylcholinesterase and K, k, Kp a and Kp b on the Kell glycoprotein.

Characterization of murine monoclonal antibodies directed against the Kell blood group glycoprotein

Murine monoclonal antibodies (MoAbs) were produced against the blood group KEL1 glycoprotein (93 kD component) immunopurified from human erythrocytes. One monoclonal antibody, 5A11 (IgGa, kappa), detects by immunoblotting a 93 and 184 kD component from KEL: 1,-2 or KEL: -1,2 red cell membrane preparations, separated by SDS polyacrylamide gel electrophoresis (PAGE) under non-reducing conditions. The 184 kD component was not detected under reducing conditions, suggesting that it represented a dimer of the 93 kD KEL glycoprotein. Neither the 93 nor the 184 kD could be detected from K0 or McLeod erythrocyte membrane preparations, indicating that the monoclonal antibody reacts with the KEL glycoprotein previously identified as a 93 kD species. Since this antibody does not agglutinate native or protease-treated erythrocytes, it is likely that it reacts with the cytoplasmic domain of the KEL glycoprotein. This was also substantiated by showing that 5A11 could immunoprecipitate the 93 kD component from intact membranes and inside-out vesicles but not from right-side-out vesicles. Immunostaining of membrane proteins prepared from human blood cells (platelets, lymphocytes, monocytes and granulocytes) and non-human erythrocytes revealed that the 93 kD molecule was only present on human red cells. Several other murine monoclonal antibodies obtained from the same fusion experiment gave identical results, but competition analyses on immunoblots indicated that these antibodies reacted with distinct epitopes on the KEL glycoprotein.